Patients with SARS-CoV-2 and HBV co-infection are at risk of greater liver injury

Yong Lin; Jun Yuan; Quanxin Long; Jieli Hu; Haijun Deng; Zhenyu Zhao; Juan Chen; Mengji Lu; Ailong Huang

doi:10.1016/j.gendis.2020.11.005

您当前的位置：

首页 >

文章列表页 >

Patients with SARS-CoV-2 and HBV co-infection are at risk of greater liver injury

更新时间：2022-06-24

- Patients with SARS-CoV-2 and HBV co-infection are at risk of greater liver injury
- Genes & Diseases Vol. 8, Issue 4, (2021)
- 作者机构：
  
  1. Key Laboratory of Molecular Biology of Infectious Diseases (Chinese Ministry of Education), Chongqing Medical University,Chongqing,PR China,400016
  2. School of Public Health and Management, Chongqing Medical University,Chongqing,PR China,400016
  3. Institute for Virology, University Hospital of Essen, University of Duisburg-Essen, Essen,Germany,45122
- 作者简介：
- 基金信息：
- DOI：10.1016/j.gendis.2020.11.005
  CLC：
- Published：2021，
  
  Published Online：1 July 2021，
扫描看全文
Yong Lin, Jun Yuan, Quanxin Long, et al. Patients with SARS-CoV-2 and HBV co-infection are at risk of greater liver injury. [J]. Genes & Diseases 8(4).(2021)
DOI：

Yong Lin, Jun Yuan, Quanxin Long, et al. Patients with SARS-CoV-2 and HBV co-infection are at risk of greater liver injury. [J]. Genes & Diseases 8(4).(2021) DOI： 10.1016/j.gendis.2020.11.005.

摘要

Abstract

To date

it remains unclear if severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) co-infection exacerbates liver injury in patients with chronic hepatitis B virus (HBV) infection. In this study

we present a retrospective study of 133 hospitalized confirmed mild coronavirus disease 2019 (COVID-19) cases

including 116 patients with COVID-19 with negative serum hepatitis B antigen and 17 HBV inactive carriers with COVID-19. We found that there were no significant differences for the discharge rate or duration of hospitalization between the two groups. However

inactive HBV carriers with SARS-CoV-2 co-infection are at a higher risk of abnormal liver function tests. The enhanced liver injury induced by SARS-CoV-2 and HBV co-infection was identified as the hepatocyte type rather than the cholangiocyte type. Moreover

the inflammatory response

including abnormal lactate dehydrogenase

D-dimer and interleukin-6 production

may contribute to this injury following SARS-CoV-2 co-infection. Collectively

SARS-CoV-2 and HBV co-infection exacerbates liver function of the patients with COVID-19.

关键词

Keywords

Abnormal liver functionCOVID-19HBVInactive HBV carriersLiver injurySARS-Cov-2

references

查看原文

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

COVID-19 therapeutics: Clinical application of repurposed drugs and futuristic strategies for target-based drug discovery

Advances of CRISPR-Cas13 system in COVID-19 diagnosis and treatment

Single-cell transcriptome landscape and antigen receptor dynamic during SARS-CoV-2 vaccination

Pandemic COVID-19: Current status and challenges of antiviral therapies

Coronavirus disease 2019 (COVID-19): cytokine storms, hyper-inflammatory phenotypes, and acute respiratory distress syndrome

Related Author

Sunny Kumar

Malini Basu

Pratyasha Ghosh

Uttam Pal

Mrinal K. Ghosh

Qianqian Zhou

Yanhua Chen

Ruolei Wang

Related Institution

Department of Microbiology, Dhruba Chand Halder College, Dakshin Barasat, West Bengal

Cancer Biology and Inflammatory Disorder Division, Council of Scientific and Industrial Research-Indian Institute of Chemical Biology (CSIR-IICB), TRUE Campus, CN-6, Sector–V, Salt Lake, Kolkata-700091 & 4, Raja S.C. Mullick Road, Jadavpur, Kolkata

Department of Economics, Bethune College, University of Calcutta, Kolkata

Academy of Integrative Medicine, Shanghai University of Traditional Chinese Medicine

State Key Laboratory of Agricultural Microbiology, College of Fisheries, Huazhong Agricultural University

⁰